Atypical Pyoderma Gangrenosum with Ulcerative Colitis treated successfully with prednisolone and mesalazine: A case report
Article Sidebar
Main Article Content
Abstract
Introduction: Pyoderma Gangrenosum (PG) manifests as recurrent deep ulceration of the skin and PG is often associated with a variety of systemic diseases, such as Inflammatory Bowel Diseases (IBD), inflammatory arthropathies, hematologic malignancies and hepatitis. There has been neither laboratory finding nor histological feature diagnostic of PG, and diagnosis of PG is mainly made based on the exclusion criteria.
Patient and methods: A male patient 21 years old, complained of rectal bleeding of 3 weeks duration. He presented with a large, painful and rapidly progressive cutaneous ulcer in the right flank. Laboratory and microbiological investigations, colonoscopic biopsy and a skin biopsy from the ulcer were performed.
Results: An atypical presentation of PG with Ulcerative Colitis (UC) was diagnosed. The PG rapidly resolved after starting treatment with prednisolone and mesalazine and the ulcer healed with scar. After successful treatment the patient suddenly stopped all his treatment and he came back again with rectal bleeding and a rounded, painful and rapidly progressive cutaneous ulcer in each cheek. One month after starting prednisolone and mesalazine treatment, complete healing of both ulcers has occurred.
Conclusion: A rare atypical presentation of PG with risk of misdiagnosis and the rapid healing of PG with combination of prednisolone and mesalazine therapy were concluded.
Downloads
Article Details
Copyright (c) 2021 Abou-Taleb DAE, et al.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing and protecting the author rights is the central aim and core of the publishing business. Peertechz dedicates itself in making it easier for people to share and build upon the work of others while maintaining consistency with the rules of copyright. Peertechz licensing terms are formulated to facilitate reuse of the manuscripts published in journals to take maximum advantage of Open Access publication and for the purpose of disseminating knowledge.
We support 'libre' open access, which defines Open Access in true terms as free of charge online access along with usage rights. The usage rights are granted through the use of specific Creative Commons license.
Peertechz accomplice with- [CC BY 4.0]
Explanation
'CC' stands for Creative Commons license. 'BY' symbolizes that users have provided attribution to the creator that the published manuscripts can be used or shared. This license allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author.
Please take in notification that Creative Commons user licenses are non-revocable. We recommend authors to check if their funding body requires a specific license.
With this license, the authors are allowed that after publishing with Peertechz, they can share their research by posting a free draft copy of their article to any repository or website.
'CC BY' license observance:
|
License Name |
Permission to read and download |
Permission to display in a repository |
Permission to translate |
Commercial uses of manuscript |
|
CC BY 4.0 |
Yes |
Yes |
Yes |
Yes |
The authors please note that Creative Commons license is focused on making creative works available for discovery and reuse. Creative Commons licenses provide an alternative to standard copyrights, allowing authors to specify ways that their works can be used without having to grant permission for each individual request. Others who want to reserve all of their rights under copyright law should not use CC licenses.
Vacas AS, Torre AC, Bollea-Garlatti ML, Warley F, Galimberti RL (2017) Pyoderma gangrenosum: clinical characteristics, associated diseases, and responses to treatment in a retrospective cohort study of 31 patients. Int J Dermatol 56: 386-391. Link: https://bit.ly/3eGNbI5
Pereira N, Brites MM, Goncalo M, Tellechea O, Figueiredo A (2013) Pyoderma gangrenosum - a review of 24 cases observed over 10 years. Int J Dermatol 52: 938-945. Link: https://bit.ly/3eBme8v
Marzano AV, Ishak RS, Saibeni S, Crosti C, Meroni PL, et al. (2013) Autoinflammatory skin disorders in inflammatory bowel diseases, pyoderma gangrenosum and Sweet's syndrome: a comprehensive review and disease classification criteria. Clin Rev Allergy Immunol 45: 202-210. Link: https://bit.ly/3iu99Pz
Yasin F, Assad S, Zahid M, Malik SA (2017) Extensive pyoderma gangrenosum: a challenging diagnosis and literature review of management. Cureus 9: e1486. Link: https://bit.ly/36NaMCr
Marzano AV, Borghi A, Wallach D, Cugno M (2018) A comprehensive review of neutrophilic diseases. Clin Rev Allergy Immunol 54: 114-130. Link: https://bit.ly/3iu9dih
Ahn C, Negus D, Huang W (2018) Pyoderma gangrenosum: a review of pathogenesis and treatment. Expert Rev Clin Immunol 14: 225-233. Link: https://bit.ly/36RR8oU
Brunsting LA, Underwood LJ (1949) Pyoderma vegetans in association with chronic ulcerative colitis. Arch Derm Syphilol 60: 161-172. Link: https://bit.ly/3kFyQzy
Ahronowitz I, Harp J, Shinkai K (2012) Etiology and management of pyoderma gangrenosum. Am J Clin Dermatol 13: 191-211. Link: https://bit.ly/3hT4CXV
TripodiCutrì F, Salerno R, Lo Schiavo A, Gravina AG, Romano M, et al. (2009) Ulcerative colitis associated with leukocytoclastic vasculitis of the skin. Dig Liver Dis 41: e42- e44. Link: https://bit.ly/3hVi7GK
Nishiwaki T, Ina K, Goto H, Watanabe O, Tsuzuki T, et al. (2005) Possible involvement of the interleukin-15 and interleukin-15 receptor system in a heightened state of lamina propria B cell activation and differentiation in patients with inflammatory bowel disease. J Gastroenteral 40:128-136. Link: https://bit.ly/3xWCFnA
Oka M (2007) Pyoderma gangrenosum and interleukin 8. Br J Dermatol 157: 1279-1281. Link: https://bit.ly/3zlZDoK
Ashchyan HJ, Butler DC, Nelson CA, Noe MH, Tsiaras WG, et al. (2018) The association of age with clinical presentation and comorbidities of pyoderma gangrenosum. JAMA Dermatol 154: 409-413. Link: https://bit.ly/3eBXT2I
Alavi A, French LE, Davis MD, Brassard A, Kirsner RS (2017) Pyoderma gangrenosum: an update on pathophysiology, diagnosis and treatment. Am J Clin Dermatol 18: 355-372. Link: https://bit.ly/3BzPTcm
Futami H, KodairaM, Furuta T, Hanai H, Kaneko E (1998) Pyoderma gangrenosum complicating ulcerative colitis: Successful treatment with methylprednisolone pulse therapy and cyclosporine. J Gastroenteral 33: 408-411. Link: https://bit.ly/3rskzYq
Reichrath J, Bens G, Bonowitz A, Tilgen W (2005) Treatment recommendations for pyoderma gangrenosum: an evidence based review of the literature based on more than 350 patients. J Am Acad Dermatol 53: 273-283. Link: https://bit.ly/3eEvedo
Sandborn WJ (2008) Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations? J Clin Gastroenterol 42: 338-344. Link: https://bit.ly/3hTeqkP
Lee JI, Park HJ, Lee JY, Cho BK (2010) A Case of Pyoderma Gangrenosum with Ulcerative Colitis Treated with Mesalazine. Ann Dermatol 22: 422-425. Link: https://bit.ly/36QJLy4
Sanders CJ, Hulsmans RF (1993) Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis 51: 262-264. Link: https://bit.ly/2W5cJIz